Weighing Dose‐Related Benefits and Risks of Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.70022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Brian Meng-Hsun Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Hydroxychloroquine, Lupus Erythematosus, Systemic, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Science and Technology Council of Taiwan, National Science and Technology Council.
Abstract (Originalsprache)
Objective To weigh higher‐dose hydroxychloroquine (HCQ; ≥400 mg/day) and lower‐dose HCQ (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California.
- Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- School of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago.
ORCID-Profile: Brian Meng-Hsun Li, Edward Chia-Cheng Lai, Meng-Yu Weng
Förderung
- National Science and Technology Council of Taiwan
- National Science and Technology Council
Zitieren
APA
Li, B. M., Hung, J. H., Yang, P. C., Lin, S. J., Lai, E. C., & Weng, M. Y. (2026). Weighing Dose‐Related Benefits and Risks of Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. https://doi.org/10.1002/art.70022
Vancouver
Li BM, Hung JH, Yang PC, Lin SJ, Lai EC, Weng MY. Weighing Dose‐Related Benefits and Risks of Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2026. doi:10.1002/art.70022
BibTeX
@article{Li2026,
author = {Li, Brian Meng-Hsun and Hung, Jia-Horung and Yang, Po-Cheng and Lin, Swu-Jane and Lai, Edward Chia-Cheng and Weng, Meng-Yu},
title = {Weighing Dose‐Related Benefits and Risks of Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70022}
}
EUVIMED